Therapeutic effect of tiotropium bromide powder inhalation in patients with stable bronchiectasis.
- Author:
Xiao-ling LI
1
;
Shao-xi CAI
;
Hai-jin ZHAO
;
Li-min DONG
;
Xiang-bo SHEN
;
Lai-yu LIU
;
Guo-dong HU
Author Information
- Publication Type:Clinical Trial
- MeSH: Administration, Inhalation; Adult; Aged; Bronchiectasis; drug therapy; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Powders; Receptor, Muscarinic M3; antagonists & inhibitors; Scopolamine Derivatives; administration & dosage; Tiotropium Bromide
- From: Journal of Southern Medical University 2010;30(5):1072-1074
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the therapeutic effect of tiotropium bromide powder inhalation on stable bronchiectasis.
METHODSTwenty-two patients with stable bronchiectasis received inhalation of totropium bromide powder at the daily dose of 18 microg, and on days 1 and 28, the patients were examined for forced expiratory volume in one second (FEVl), predicted value [FEVl(%)], forced expiratory volume (FEV), and FEVl/FVC. The symptom score and BODE index were also recorded.
RESULTSAfter 1 month of inhalation therapy, the FEV1% of the patients showed a moderate increase but the increment was not statistically significant (t=-1.875, P>0.05); the symptom score and BODE index decreased significantly after the therapy (t=7.091, P<0.001; t=2.982, P<0.05).
CONCLUSIONLong-term inhalation of tiotropium bromide powder can improve the clinical symptoms and BODE index and enhance the exercise tolerance and quality of life of the patients with bronchiectasis.
